Similarly, secondary prevention studies such as the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) study show the use of higher statin doses (Atorvastatin 80 mg versus Pravastatin 40 mg) to significantly lower both LDL-C and CRP levels after 18 months of therapy. The gene discussed is CRP; the disease is atherosclerosis.